January 23 , 2024 - Jiangsu Recbio Technology Co., Ltd.  ("Recbio" , HKEX:02179) is pleased to announce that the company has recently reached a License and strategic cooperation with the Saudi Arabian pharmaceutical company SPIMACO for the recombinant HPV-9 vaccine REC603. According to the agreement, Recbio exclusively authorizes SPIMACO to develop, register and commercialize the HPV-9 vaccine REC603 in 15 Middle East and North African countries, including Saudi Arabia.

This strategic cooperation covers a total population of approximately 380 million in the Middle East and North African countries. Cervical cancer is the eighth most common cancer in Saudi Arabia and the eighth most common chronic cancer among women aged 15-44. The nine-valent HPV vaccine is widely regarded as the most effective vaccine against HPV and can prevent about 90% of cervical cancer and 90% of anal and genital warts. SPIMACO is one of the largest listed pharmaceutical companies in Saudi Arabia. The company is deeply involved in the government-funded and private self-pay markets in the Middle East and North Africa, and its products widely cover the Middle East and North Africa countries. The cooperation between the Company and SPIMACO will help the Company explore the Middle East, North Africa and other markets and accelerate the commercialization process of innovative vaccines.

The company's core product, the recombinant nine-valent HPV vaccine REC603, is suitable for people aged 9 to 45 years old. It has shown good safety and immunogenicity in previous studies and is currently in the Phase III clinical stage in China. REC603 uses Hansenula yeast expression system, which can achieve high production and stable expression of HPV virus-like particles, making the company's vaccine candidate more suitable for commercial production. The company's HPV vaccine manufacturing facility is constructed in accordance with the requirements of the WHO pre-qualification (WHO PQ) system and can meet the annual production capacity of up to 20 million doses of recombinant HPV-9 vaccine.

Source:

https://mp.weixin.qq.com/s/3OsLpY-mIAOgrpLmBACQ2w